2Pamukkale University, Seed Breeding and Genetic Application and Research Centre, Denizli-Turkey
3Department of Biomedical Engineering, Pamukkale University, Faculty of Technology, Denizli-Turkey
4Department of Molecular Biology and Genetics, Abdullah Gül University, Faculty of Life and Natural Sciences, Kayseri-Turkey DOI : 10.5505/tjo.2020.2380
Summary
OBJECTIVEDefects in apoptotic cell death which restrict the success of conventional cytotoxic therapies have pivotal roles in a number of pathological conditions including cancer. However, a novel drug class targeting pro-survival Bcl-2 protein family members has been developed with the understanding of the structures and interactions of Bcl-2 proteins. Within this new class, Bcl-2/Bcl-xL inhibitor Navitoclax and Bcl-2 specific inhibitor Venetoclax have been shown to demonstrate strong anticancer activities on several types of cancers. But their low affinity to other anti-apoptotic proteins limits their clinical usage. Here, we investigated the cytotoxic and apoptotic effects of Navitoclax/Venetoclax and their combinations with specific tyrosine kinase inhibitor Apatinib on estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cell lines.
METHODS
MTT assay was used for the evaluation of the inhibition of cancer cell proliferation. ELISA test and
Quantitative real-time PCR assay was performed to determine the role of caspase-3, Bak, Bax, Bcl-2,
Bcl-xL and Mcl-1 proteins in the inhibition of cell proliferation triggered by the tested agents.
RESULTS
We found that aggressive MDA-MB-231 cell line was more sensitive to all tested agents. Apatinib significantly
enhanced Navitoclax/Venetoclax mediated inhibition of cell viability in both cancer cell lines
despite up-regulation in the expression levels of Bcl-2 and Mcl-1 genes. We further demonstrated significant
Bak/Bax and caspase-3 expression in less aggressive MCF-7 cells.
CONCLUSION
Our findings have impacts on Navitoclax/Venetoclax plus Apatinib based therapy for breast adenocarcinoma.
On the other hand, further studies should be conducted to elucidate the mechanisms underlying
synergistic effects of Navitoclax/Venetoclax plus Apatinib combinations.
Introduction
Cancer, widely known as the "disease of the age" is a complex genetic disorder defined as the conversion of a normal/healthy cell to a malignant one as a result of various genetic changes such as mutations seen in onco- and tumor suppressor genes, and developing resistance to death, especially apoptosis.[1,2] The connection between the induction of apoptotic cell death and elimination of potential malignant cells, hyperplasia, and tumor progression dates back to the early 1970s.[3] Today, it is known that escape from apoptosis is crucial in the transformation process to malignancy [4] and therefore the focus is on new approaches targeting apoptosis regulation in cancer treatment. [5-7] Apoptosis is the primary type of programmed cell death induced when DNA damage is beyond repair. The induction of apoptosis takes place through two main pathways, namely the extrinsic and intrinsic pathways.[8] In the case of intrinsic pathway, various stimuli directly affect their targets within the cell and a series of events are initiated by the mitochondria. Basically, all these stimuli cause the mitochondrial permeability transition pores to open, a decrease in mitochondrial transmembrane potential, and consequently, the release of pro-apoptotic factors to the cytosol to induce cellular death. The regulation of mitochondrial pores is mainly governed by the Bcl-2 family proteins consisting of a series of evolutionarily conserved proand anti-apoptotic members that share Bcl-2 homology (BH) domains. Among the pro-apoptotic members, BH3-only proteins are the ones which share only a small region of homology, the third Bcl-2 homology (BH3) domain, with other Bcl-2 family members. The so-called BH3-only proteins exert their pro-apoptotic functions both by neutralizing the effects of other antiapoptotic relatives and activating pro-apoptotic members with multi-BH domains, which make them valuable in breaking the resistance of cancer cells against apoptotic death. Nevertheless, many types of tumors, particularly those that are resistant to treatment, express one or more of anti-apoptotic members at very high levels and also carry mutations that inhibit the induction of BH3-only proteins.[9] On the other hand, upon understanding the structures and interactions of many Bcl-2 protein family members, it has become possible to develop new generation BH3 mimetics that may be alternative to traditional chemotherapy.[10-15]In this study, we aimed to assess the cytotoxic and apoptotic effects of clinically available navitoclax (NTX) and venetoclax (VTX), which are members of BH3 mimetics, and also their combination with apatinib (APTB) on estrogen receptor (ER)-positive MCF- 7 and ER-negative MDA-MB-231 breast cancer cell lines. Previous studies showed that both BH3 mimetics have therapeutic properties on some hematological malignancies, but various solid tumors develop resistance to these drugs due to especially the increased expression of Mcl-1, which is an anti-apoptotic member of the Bcl-2 protein family.[16-18] The APTB combination with BH3 mimetics in the scope of present work is a powerful inhibitor of the signal transduction pathway dependent on vascular endothelial growth factor (VEGF). VEGF is shown as a major angiogenic factor in human cancers and is associated with failures in treatment.[19] As a matter of fact, it has been known for a long time that serum and plasma VEGF levels of metastatic breast cancer patients are also quite high. [20] Since VEGF is also known to up-regulate Mcl- 1 protein,[21] it has been thought that the combined application of the VEGF inhibitor APTB with the socalled BH3 mimetics may offer a potential alternative approach to traditional chemotherapy in breast cancer treatment.
Methods
Cell CultureThe human breast adenocarcinoma cell lines (MCF- 7 and MDA-MB-231) were obtained from American Type Culture Collection (ATCC, USA). Both cell lines were cultured with high-glucose DMEM supplemented with 100 IU/ml penicillin, 100 ?g/ml streptomycin and 20% fetal bovine serum (FBS) in a humidified atmosphere of 95% air with 5% CO2 at 37°C.
Cell Proliferation Assay
The effects of NTX and VTX, and also their combination
with APTB on the proliferation of breast cancer cell
lines were detected by MTT assay. Briefly, MCF-7 and
MDA-MB-231 cells were seeded into 96-well plates at a
density of 1x104 per well and allowed to attach for 24 h
before treatment. The cells were exposed to various concentrations
of NTX, VTX and APTB (0-100 µM) alone
or in combination for 24 h (The sole treatment of APTB
was carried out to determine non-toxic concentrations
of the inhibitor for further combined applications). After
incubation period, MTT solution (5 mg/ml PBS) was
added and the plates were located in an incubator with
5% CO2 at 37 ºC. After 4 h, MTT-formazan crystals were
dissolved in DMSO and then cell growth was assessed
by measuring the absorbance at 570 nm. Cell viability
was expressed as percentage survival, with 100% survival
taken as that observed in related control cells which
were treated with 0.1% and 0.2% DMSO for alone and
combined treatments, respectively.
Mcl-1 Protein Levels
Samples were assayed for Mcl-1 levels by using a commercially
available ELISA kit (RayBiotech, Inc., Norcross, GA, USA). Briefly, 100 µl of each standard or
sample were added to appropriate wells of the plate
pre-coated with an antibody specific for human Mcl-1.
The plate was incubated for 2.5 h at room temperature,
washed, and then all wells received 100 µl biotinylated
antibodies. Following 1 h incubation at room temperature,
plate was washed, 100 µl Streptavidin solutions
were added to each well and incubated for 45 min at
room temperature. After repetition of the washing step,
100 µl of TMB One-Step Substrate reagent was added
to each well for color development and incubated for
30 min at room temperature. The reaction was stopped
by adding 50 µl Stop solution to each well and the optical
density was measured at 450 nm. A Mcl-1 standard
curve was generated to quantitate the amount of Mcl-1
in ng/ml.
RNA Isolation and Quantitative Real Time PCR
(qRT-PCR)
RNA extraction from the samples was performed by
using RNeasy Plus Universal RNA Isolation Kit following
the manufacturer's protocol with slight modifications
(Qiagen, Redwood City, CA, USA). The RNA
concentration was determined using a NanoDrop
(MaestroNano micro-volume Spectrophotometer,
USA) and the RNA was reverse transcribed using a RevertAid
Reverse Transcriptase (ABM).[22] cDNA was
stored at -80ºC for further use.
qRT-PCR analysis was carried out using SYBR Green qPCR Master Mix (GM, Taiwan) in an Exicycler 96 Real Time Quantitative Thermal Block PCR System (Bioneer, Daejeon, Korea). Beta-actin (ACTB) gene was chosen from the group of housekeeping genes to normalize gene expression. The primer sequences for the target genes and amplification conditions were given in Table 1.
;){kind=link}
Table 1: Primer sequences and amplification conditions
Statistical Analysis
The data are presented as the mean±S.E.M of three
experiments. The differences in variance were analyzed
statistically using a one-way analysis of variance
(ANOVA) test by Graphpad prism 5.0 statistics software
(GraphPad, La Jolla, CA, USA). Tukey's test was
used as a post hoc.
Results
The Effects of BH3 Mimetics and Their Combinations with Apatinib on the Proliferation of Human Breast Cancer Cell LinesFirstly, the effects of the BH3 mimetics and APTB alone on the cell viability of human breast cancer cells were investigated. For this purpose, MCF-7 and MDAMB- 231 cell lines were exposed to the drugs in the concentration range of 0-100 ?M for 24 h and the results were presented in Figure 1 and 2, respectively. As can be seen from these figures, APTB was found non-toxic for both cell lines at the concentrations of 2.5 and 5 µM and MDA-MB-231 cells were more sensitive than MCF-7 cell line to higher concentrations of the inhibitor. The results displayed that while the dose range of NTX with increased cytotoxicity was determined as 0-50 and 0-5 µM on MCF-7 and MDA-MB-231 cells, respectively, it was 0-50 µM for VTX on both cell lines.
;){kind=link}
;){kind=link}
Interestingly, more aggressive MDA-MB-231 cells showed resistance to NTX at higher concentrations and cell viability could not be reduced to below 48% by increasing the mimetic concentration. Importantly, it should be stated that relatively low concentrations of both mimetics, 2.5 and 5 µM, could not reduce cell viability of both two cell lines to less than 50% compared to the their control groups.
To obtain more effective results in this relatively low concentration range (0-5 µM), NTX and VTX were combined with the non-toxic concentrations of APTB (Figs. 3, 4). While MCF-7 cell proliferation could not be decreased below 50% with these combined treatments, it was acquired for MDA-MB-231 cell line with NTX plus APTB applications. In the case of MCF-7, there were no significant differences between the groups with increased NTX plus constant APTB concentrations or vice versa. On the other hand, approximately 58% cell viability was determined in 0.5 µM NTX plus APTB treatments as with alone 5 µM NTX treatment (Fig. 3a). These findings are significant in terms of getting similar results with much lower concentration of the mimetic. Unlike from NTX-APTB combined applications, it was found that the most cytotoxic 5 µM VTX plus 5 µM APTB treatment had also significantly lower levels of cell viability than 5 µM VTX plus 2.5 ?M APTB group (p<0.05) (Fig. 3b). When it comes to MDA-MB-231 cell line, it was clearly seen that 2.5 µM APTB combinations did not provide significant improvement to the toxicity of VTX. However, when 2.5 µM VTX were combined with 5 µM APTB, cell viability was significantly decreased from about 77% to about 63% (p<0.05). The effectiveness of the so-called combined application was not able to significantly increase by increasing VTX concentration to 5 µM (Fig. 4b). Finally, Figure 4a shows that cell viability was about 45% in 0.5 µM NTX plus 5 µM APTB treatment and this value could not be significantly decreased by increasing NTX concentration as in the case of VTX. When all above-mentioned results were evaluated together, the apoptotic effects of 0.5 µM NTX plus 2.5 µM APTB, 0.5 µM NTX plus 5 µM APTB and 5 µM VTX plus 5 µM APTB on MCF-7, and 0.5 µM NTX plus 5 µM APTB and 2.5 µM VTX plus 5 µM APTB combinations on MDA-MB-231 cell line were further investigated compared to the sole applications.
;){kind=link}
;){kind=link}
The Effects of BH3 Mimetics and Their Combinations
With Apatinib on the Mcl-1 Protein Levels of
Human Breast Cancer Cell Lines
As stated above, similar or better results in cytotoxicity
assessment with much lower concentrations of BH3
mimetics could be obtained by combining these mimetics
with non-toxic dosages of APTB. To enlighten
the role of Mcl-1 protein levels in these synergic cytotoxic
effects of the so-called combinations, the changes
in these protein levels were determined with ELISA
kit and compared with alone treatments. As is known,
Mcl-1 is one of the anti-apoptotic members of the Bcl-2
protein family which regulates mitochondrial pore formation
and among the factors that are held responsible
for the resistance of solid tumors to BH3 mimetics.[9] The results were presented in Figure 5. Among comparable
groups, the only significant difference was found
between control and 5 µM VTX and between 2.5 and
5 µM APTB groups of MCF-7 cells (p<0.05). Unfortunately,
significant decreases in Mcl-1 protein levels
could not be attained with the application of combined
treatments in both cell lines.
;){kind=link}
The Effects of BH3 Mimetics and Their Combinations
With Apatinib on Pro- and Anti-Apoptotic
Gene Regulation of Human Breast Cancer Cell Lines
Transcriptional regulation of pro-apoptotic caspase-3
(Cas3), Bak and Bax, and anti-apoptotic Bcl-2, Bcl-xL
and Mcl-1 genes in two different human breast cancer
cell lines which were exposed to BH3 mimetic and
APTB alone or in combination at the concentrations
determined as mentioned above were investigated. As
very well known, all studied genes except Cas3 are the
members of the Bcl-2 gene family. The effector protein
Cas3 can be considered as the intersection and the last
step of different apoptotic cell death cascades. The effects
of the agents and their combinations on the transcriptional
regulation of the specified genes in MCF-7
and MDA-MB-231 cell lines are presented in Tables 2
and 3, respectively. From the obtained results, it was
seen that to combine 0.5 µM NTX with 2.5 µM APTB caused significant induction in the expression of proapoptotic
adaptor Bak and Bax proteins when compared
with both control group and alone 0.5 µM NTX
and 2.5 µM APTB applications (p<0.0001) in MCF-7
cell line. However, this combined treatment also significantly
induced anti-apoptotic Bcl-2 and Mcl-1 expression
compared with control. When 0.5 µM NTX
or 2.5 µM APTB was applied alone, either there was
no significant change or significantly lower induction
by comparison with the so-called combined treatment
(p<0.0001) were observed in the expression levels of
these anti-apoptotic genes, respectively. On the other hand, when we consider the interactions between proand
anti-apoptotic relatives of Bcl-2 protein family,[9]
this situation can be interpreted as the response against
increased Bax and Bak protein expression. Surprisingly,
to increase APTB concentration from 2.5 to 5 µM in
the combined application also gave rise to induction in
the expression of Bcl-2 and Mcl-1 proteins without any
induction in pro-apoptotic ones. Differently from NTX
plus APTB combination, 5 µM APTB combination of 5
µM VTX could significantly increase Cas3 expression
besides significant induction in the expression of Bak
and Bax. As indicated in Table 2, although higher induction
in Bak and Bax expression were observed in 5
µM VTX when compared to combined treatment, Cas3
expression did not significantly increase. So, it would
not be wrong to say that VTX and APTB combination
showed synergistic effect in terms of apoptotic death
of human breast cancer cell MCF-7. Unfortunately, the
highest induction in the anti-apoptotic gene expression
was also found for this combination, which can be
commented as a parameter reducing the effectiveness
of this dual drug administration. Contrary to the promising
results seen on MCF-7, no significant increases in
pro-apoptotic gene expression have been observed in
combined applications performed on MDA-MB-231
cell line (Table 3). Conversely, the sharpest increase in
Bcl-2 gene expression and significant down regulation
in Cas3 were determined in this cell line that treated
with 5 µM APTB + 0.5 µM NTX. The significant down
regulation of Mcl-1 gene in the same combined group
also could not be seen as an improved resistance to survival
due to the similar results that obtained both in
the alone 5 µM APTB and 0.5 µM NTX treated groups.
Although, significant up-regulation of Bcl-xL gene in
0.5 µM NTX group was repressed by the combination
with 5 µM APTB, it is clear that higher sensitivity of more aggressive MDA-MB-231 cells to the combined
tested agents rather than MCF-7 is independent from
the factors investigated.
;){kind=link}
;){kind=link}
Table 2: The expression level of the selected genes in MCF-7 cell line
Table 3: The expression level of the selected genes in MDA-MB-231 cell line
Discussion
The Bcl-2 protein family controls the mitochondrial pathway of apoptotic cell death depend on the levels and interactions of its pro- and anti-apoptotic members. On the other hand, the findings obtained until now show us that several anti-apoptotic Bcl-2 family proteins, such as Bcl-2, Bcl-xL and Mcl-1 are expressed at high levels in many cancer types including breast adenocarcinoma.[23-27] Hence, it is crucial to specifically target these anti-apoptotic proteins in terms of developing novel and effective treatments with fewer side effects. In this context, the mimetics of BH3-only proteins are thought to be powerful agents against cancer.[9] NTX, which can target Bcl-2/Bcl-xL, and Bcl- 2 specific VTX are among the BH3 mimetics which were proved to be active in lymphoid malignancies and studies which are being conducted on for other types of tumors.[28-31] Of course, it should be remembered that the impression of any BH3 mimetic can extend beyond its targeted protein.[32-34] Nevertheless, other non-targeted anti-apoptotic members, such as Mcl- 1, are held responsible for the resistance of especially solid tumors to these drugs and focus is on combined studies.In the current study, we analyzed the cytotoxic and apoptotic effects of NTX/VTX and their combination with APTB on two different breast cancer cell lines with different aggressiveness for the first time. We observed that 0?5 ?M APTB alone was non-toxic on both MCF-7 and MDA-MB-231 cell lines and the latter one was more sensitive to the agent in its higher doses within 24 h. In a recent study of Gao et al., supportive cytotoxicity results were shown on MDA-MB-231 cells for 72 h.[35] It was determined that APTB exerted dose-dependent inhibition of MCF-7 cell growth at the concentrations higher than 2 µM after 48 h treatment, which is also compatible with our data.[36] According to the literature, APTB shows its cytotoxic effect on cancer cells by blocking the phosphorylation of VEGFR-2 and thereby restraining several signaling pathways.[37] On the other hand, as stated previously, it was found that there has been correlation between VEGF and Mcl-1 expressions on certain hematological malignancies,[21,38] which give rise to thought that BH3 mimetics plus APTB can show synergistic effects in terms of inhibition of solid tumor cell proliferation. As a matter of fact, we found that to combine NTX/ VTX with non-toxic concentrations of APTB significantly reduced the mimetic concentrations required to achieve similar or higher cytotoxic effects when compared to their sole applications. In other words, APTB combination sensitized the cells against the so-called BH3 mimetics in correlation with their aggressiveness. Tutusaus et al., indicated the synergistic effect of NTX plus sorafenib, a multikinase inhibitor, on hepatocellular carcinoma depend on the changes in the Bcl-2 protein profile.[39] In another recent study, tyrosine kinase inhibitors were shown to drive prostate cancer apoptosis when they were combined with Bcl-xL/ Bcl-2 inhibitors by increasing Mcl-1 degradation.[40] However, we observed significant up-regulation in Bcl-2 expression in both MCF-7 and MDA-MB-231 cell lines, which were exposed to the combined treatments. Mcl-1 expression was also significantly up-regulated in MCF-7 cells. For these reasons, we could not explain the synergistic cytotoxic effects of NTX/VTX plus APTB over the changes in Bcl-2 and Mcl-1 gene expression against human breast cancer cells. After all, the more sensitivity of aggressive MDA-MB-231 cells to the so-called combined applications and significant Bak/Bax and Cas3 expression in less aggressive MCF- 7 cells can be seen as encouraging results. So, we can suggest that VTX/NTX plus APTB in their indicated low concentrations might be used efficaciously on human breast cancer cells but further studies are needed to clearly elucidate the observed synergistic cytotoxic effects.
Conclusion
Our results suggested that NTX/VTX and APTB showed cytotoxic effects on breast cancer cell lines depending on cell aggressiveness. Additionally, in this study, it was demonstrated that APTB sensitized breast cancer cells to low doses of NTX/VTX again in correlation with the aggressivity. Hopefully, these combinations can provide new options for novel approaches to the treatment of breast cancer. However, the underlying mechanism(s) in these synergistic cytotoxic effects should be elicited with further studies.
Limitations of the Study
Within the scope of this study, expression levels of a
limited number of genes could be examined. In order
to elucidate the exact mechanisms leading to the cytotoxic
effects of the studied applications, more target
behaviors should be investigated.
Acknowledgments: This study was supported by Scientific Research Projects Unit of Pamukkale University (PAUBAP2019BSP008).
Peer-review: Externally peer-reviewed.
Conflict of Interest: None declared.
Financial Support: None declared.
Authorship contributions: Concept - B.K.Y., Ö.Ö.A., A.S., A.Ş.; Design - B.K.Y., Ö.Ö.A., A.S., A.Ş.; Supervision - B.K.Y., Ö.Ö.A., A.S., A.Ş.; Funding - B.K.Y., Ö.Ö.A., A.S., A.Ş.; Materials - B.K.Y., Ö.Ö.A., A.S., A.Ş.; Data collection &/ or processing - B.K.Y., Ö.Ö.A.; Analysis and/or interpretation - B.K.Y., Ö.Ö.A., A.S.; Literature search - B.K.Y., Ö.Ö.A.; Writing - B.K.Y., Ö.Ö.A., A.S.; Critical review - B.K.Y., Ö.Ö.A., A.S., A.Ş.
References
1) Hanahan D, Weinberg RA. The hallmarks of cancer.
Cell 2000;100(1):57-70.
2) Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B,
et al. Programmed cell death pathways in cancer: a review
of apoptosis, autophagy and programmed necrosis.
Cell Proliferat 2012;45(6):487-98.
3) Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological
phenomenon with wideranging implications in
tissue kinetics. Br J Cancer 1972;26(4):239.
4) Wong RS. Apoptosis in cancer: from pathogenesis to
treatment. J Exp Clin Cancer Res 2011;30(1):87.
5) Belmar J, Fesik SW. Small molecule Mcl-1 inhibitors
for the treatment of cancer. Pharmacol Therapeut
2015;145:76-84.
6) Sun C, Liu Z, Li S, Yang C, Xue R, Xi Y, et al. Downregulation
of c-Met and Bcl2 by microRNA-206,
activates apoptosis, and inhibits tumor cell proliferation,
migration and colony formation. Oncotarget
2015;6(28):25533.
7) Cho HD, Lee JH, Moon KD, Park KH, Lee MK, Seo KI.
Auriculasin-induced ROS causes prostate cancer cell
death via induction of apoptosis. Food Chem Toxicol
2018;111:660-9.
8) Eum KH, Lee M. Crosstalk between autophagy and
apoptosis in the regulation of paclitaxel-induced cell
death in v-Ha-ras-transformed fibroblasts. Mol Cell
Biochem 2011;348(1-2):61-8.
9) Adams JM, Cory S. The BCL-2 arbiters of apoptosis
and their growing role as cancer targets. Cell Death
Differ 2018;25(1):27.
10) Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong
RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2
family proteins induces regression of solid tumours.
Nature 2005;435(7042):677.
11) Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen
J, Jin S, et al. ABT-263: a potent and orally bioavailable
Bcl-2 family inhibitor. Cancer Res 2008;68(9):3421-8.
12) Lessene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KN,
Adams JM, et al. Structure-guided design of a selective
BCL-X L inhibitor. Nat Chem Biol 2013;9(6):390.
13) Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron
ND, Chen J, et al. ABT-199, a potent and selective
BCL-2 inhibitor, achieves antitumor activity while
sparing platelets. Nat Med 2013;19(2):202.
14) Leverson JD, Phillips DC, Mitten MJ, Boghaert ER,
Diaz D, Tahir SK, et al. Exploiting selective BCL-2
family inhibitors to dissect cell survival dependencies
and define improved strategies for cancer therapy. Sci
Transl Med 2015;7(279):279ra40-279ra40.
15) Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ.
From basic apoptosis discoveries to advanced selective
BCL-2 family inhibitors. Nat Rev Drug Discov
2017;16(4):273.
16) Li G, Zhang S, Fang H, Yan B, Zhao Y, Feng L, et al.
Aspirin overcomes Navitoclax-resistance in hepatocellular
carcinoma cells through suppression of Mcl-1.
Biochem Biophys Res Commun 2013;434(4):809-14.
17) Cerella C, Gaigneaux A, Mazumder A, Lee JY, Saland E, Radogna F, et al. Bcl-2 protein family expression
pattern determines synergistic pro-apoptotic effects
of BH3 mimetics with hemisynthetic cardiac glycoside
UNBS1450 in acute myeloid leukemia. Leukemia
2017;31(3):755-9.
18) Reinhart R, Rohner L, Wicki S, Fux M, Kaufmann
T. BH3 mimetics efficiently induce apoptosis in
mouse basophils and mast cells. Cell Death Differ
2018;25(1):204-16.
19) Foekens JA, Peters HA, Grebenchtchikov N, Look MP,
Meijer-van Gelder ME, Geurts-Moespot A, et al. High
tumor levels of vascular endothelial growth factor predict
poor response to systemic therapy in advanced
breast cancer. Cancer Res 2001;61(14):5407-14.
20) Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki
H, Kitamura M, et al. Concentrations of vascular endothelial
growth factor in the sera of normal controls
and cancer patients. Clin Cancer Res 1996;2(5):821-6.
21) Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan
D, Ishitsuka K, et al. VEGF induces Mcl-1 upregulation
and protects multiple myeloma cells against
apoptosis. Blood 2004;104(9):2886-92.
22) Yavuz S, Çetin A, Akdemir A, Doyduk D, Dişli A, Çelik
Turgut G, et al. Synthesis and Functional Investigations
of Computer Designed Novel Cladribine-Like
Compounds for the Treatment of Multiple Sclerosis.
Arch Pharm (Weinheim) 2017;350(11).
23) Noujaim D, van Golen CM, van Golen KL, Grauman
A, Feldman EL. N-Myc and Bcl-2 coexpression induces
MMP-2 secretion and activation in human neuroblastoma
cells. Oncogene 2002;21(29):4549-57.
24) Wick W, Wild?Bode C, Frank B, Weller M. BCL?2?induced
glioma cell invasiveness depends on furin-like
proteases. J Neurochem 2004;91(6):1275-83.
25) Koehler BC, Scherr AL, Lorenz S, Urbanik T, Kautz N,
Elssner C, et al. Beyond cell death-antiapoptotic Bcl-2
proteins regulate migration and invasion of colorectal
cancer cells in vitro. PloS one 2013;8(10).
26) Zhang Y, Li Y, Li H, Chen W, Liu W. Clostridium difficile
toxin B recombinant protein inhibits tumor
growth and induces apoptosis through inhibiting
Bcl-2 expression, triggering inflammatory responses
and activating C-erbB-2 and Cox-2 expression in
breast cancer mouse model. Biomed Pharmacother
2018;101:391-8.
27) Lochmann TL, Floros KV, Naseri M, Powell KM, Cook
W, March RJ, et al. Venetoclax is effective in small-cell
lung cancers with high BCL-2 expression. Clin Cancer
Res 2018;24(2):360-9.
28) Nakajima W, Sharma K, Hicks MA, Le N, Brown R,
Krystal GW, et al. Combination with vorinostat overcomes
ABT-263 (navitoclax) resistance of small cell
lung cancer. Cancer Biol Ther 2016;17(1):27-35.
29) Lindeman GJ, Lok SW, Bergin AR, Whittle JR, Shackleton
K, Sherman P, et al. Safety and efficacy of the
BCL2 inhibitor venetoclax in estrogen receptor (ER)
and BCL2-positive metastatic breast cancer: The
mBEP study. J Clin Oncol 2017;35(15 suppl):1044.
30) Kivioja JL, Thanasopoulou A, Kumar A, Kontro M,
Yadav B, Majumder MM, et al. Dasatinib and navitoclax
act synergistically to target NUP98-NSD1+/
FLT3-ITD+ acute myeloid leukemia. Leukemia
2019;33(6):1360-72.
31) Thijssen R, Roberts AW. Venetoclax in Lymphoid Malignancies:
New Insights, More to Learn. Cancer Cell
2019;36(4):341-3.
32) Moore VDG, Brown JR, Certo M, Love TM, Novina
CD, Letai A. Chronic lymphocytic leukemia requires
BCL2 to sequester prodeath BIM, explaining sensitivity
to BCL2 antagonist ABT-737. Journal Clin Invest
2007;117(1):112-21.
33) Mérino D, Khaw SL, Glaser SP, Anderson DJ, Belmont
LD, Wong C, et al. Bcl-2, Bcl-xL, and Bcl-w
are not equivalent targets of ABT-737 and navitoclax
(ABT-263) in lymphoid and leukemic cells. Blood
2012;119(24):5807-16.
34) Montero J, Letai A. Why do BCL-2 inhibitors work
and where should we use them in the clinic?. Cell
Death Differ 2018;25(1):56-64.
35) Gao Z, Shi M, Wang Y, Chen J, Ou Y. Apatinib enhanced
anti-tumor activity of cisplatin on triple-negative
breast cancer through inhibition of VEGFR-2.
Pathol Res Pract 2019;215(7):152422.
36) Zhang H, Sun J, Ju W, Li B, Lou Y, Zhang G, et al. Apatinib
suppresses breast cancer cells proliferation and
invasion via angiomotin inhibition. Am J Transl Res
2019;11(7):4460.
37) Zhao D, Hou H, Zhang X. Progress in the treatment of
solid tumors with apatinib: a systematic review. Onco-
Targets Ther 2018;11:4137.
38) Véronèse L, Tournilhac O, Verrelle P, Davi F, Dighiero
G, Chautard E, et al. Strong correlation between
VEGF and MCL-1 mRNA expression levels in Bcell
chronic lymphocytic leukemia. Leukemia Res
2009;33(12):1623-6.